Literature DB >> 2400307

Level I and II axillary dissection in the treatment of early-stage breast cancer. An analysis of 259 consecutive patients.

B M Siegel1, K A Mayzel, S M Love.   

Abstract

Level I and II axillary dissection involves anatomic dissection of levels I and II of the axilla without clearance of the axillary vein or placement of drains. The results of level I and II axillary dissection with breast conservation in a consecutive series of 259 patients treated from 1981 through 1988, with a mean follow-up of 22.5 months (median, 27.1 months) were reviewed. The number of nodes removed ranged from two to 24, with a mean of nine. Axillary seroma was the most frequent complication (11 patients [4.2%]). Lymphedema was observed in seven patients (2.7%). Axillary recurrences occurred in two patients. These results indicate that a level I and II axillary dissection defined anatomically allows prognostic evaluation while limiting morbidity and recurrence. In addition, this procedure can be done safely without drains on an outpatient basis, with further psychological and economic benefits.

Entities:  

Mesh:

Year:  1990        PMID: 2400307     DOI: 10.1001/archsurg.1990.01410210070010

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  11 in total

1.  The use of closed suction drainage after lumpectomy and axillary node dissection for breast cancer. A prospective randomized trial.

Authors:  R G Somers; L K Jablon; M J Kaplan; G L Sandler; N K Rosenblatt
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

2.  Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients.

Authors:  Emin Yildirim; Ugur Berberoglu
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

3.  Frequency of Early-Stage Lymphedema and Risk Factors in Postoperative Patients with Breast Cancer.

Authors:  Aykut Soyder; Engin Taştaban; Serdar Özbaş; Şükrü Boylu; Hedef Özgün
Journal:  J Breast Health       Date:  2014-04-01

4.  Complications of Axillary Lymph Node Dissection in Treatment of Early Breast Cancer: A Comparison of MRM and BCS.

Authors:  Preetinder Brar; Satish Jain; Iqbal Singh
Journal:  Indian J Surg Oncol       Date:  2011-07-22

5.  The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.

Authors:  Arpana M Naik; Jane Fey; Mary Gemignani; Alexandra Heerdt; Leslie Montgomery; Jeanne Petrek; Elisa Port; Virgilio Sacchini; Lisa Sclafani; Kimberly VanZee; Raquel Wagman; Patrick I Borgen; Hiram S Cody
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

6.  Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care.

Authors:  Mahmoud B El-Tamer; B Marie Ward; Tracy Schifftner; Leigh Neumayer; Shukri Khuri; William Henderson
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

7.  Long thoracic nerve injury in breast cancer patients treated with axillary lymph node dissection.

Authors:  Roser Belmonte; Sandra Monleon; Neus Bofill; Martha Ligia Alvarado; Josep Espadaler; Inmaculada Royo
Journal:  Support Care Cancer       Date:  2014-07-18       Impact factor: 3.603

8.  Scapular winging in surgical treatment of breast cancer, prospective study to optimize the follow-up protocol.

Authors:  M Ortí-Asencio; S Salinas-Huertas; A Luzardo-González; J Terra-Falótico; R Planas-Balagué
Journal:  Clin Transl Oncol       Date:  2021-04-08       Impact factor: 3.405

9.  Breast cancer in young women: poor survival despite intensive treatment.

Authors:  Hanna Fredholm; Sonja Eaker; Jan Frisell; Lars Holmberg; Irma Fredriksson; Henrik Lindman
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

10.  Seroma formation after breast cancer surgery: what we have learned in the last two decades.

Authors:  Vivek Srivastava; Somprakas Basu; Vijay Kumar Shukla
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.